Additionally, the 36-month beta value for ALVO is 0.05. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALVO is 51.35M and currently, short sellers hold a 0.37% ratio of that float. The average trading volume of ALVO on April 19, 2024 was 331.27K shares.
ALVO) stock’s latest price update
The stock price of Alvotech (NASDAQ: ALVO) has jumped by 5.12 compared to previous close of 12.89. Despite this, the company has seen a gain of 10.70% in its stock price over the last five trading days. Reuters reported 2024-02-15 that Alvotech said on Thursday it has reached settlement agreements with Johnson & Johnson for launching the biosimilar of the pharmaceutical giant’s blockbuster psoriasis drug Stelara in Japan, Canada and the European Economic Area.
ALVO’s Market Performance
ALVO’s stock has risen by 10.70% in the past week, with a monthly drop of -11.03% and a quarterly drop of -4.17%. The volatility ratio for the week is 4.58% while the volatility levels for the last 30 days are 3.90% for Alvotech The simple moving average for the past 20 days is 8.07% for ALVO’s stock, with a 21.39% simple moving average for the past 200 days.
Analysts’ Opinion of ALVO
Many brokerage firms have already submitted their reports for ALVO stocks, with Barclays repeating the rating for ALVO by listing it as a “Overweight.” The predicted price for ALVO in the upcoming period, according to Barclays is $17 based on the research report published on January 29, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see ALVO reach a price target of $10, previously predicting the price at $5. The rating they have provided for ALVO stocks is “Neutral” according to the report published on October 20th, 2023.
Barclays gave a rating of “Equal Weight” to ALVO, setting the target price at $10 in the report published on September 21st of the previous year.
ALVO Trading at -6.19% from the 50-Day Moving Average
After a stumble in the market that brought ALVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.72% of loss for the given period.
Volatility was left at 3.90%, however, over the last 30 days, the volatility rate increased by 4.58%, as shares sank -10.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.61% lower at present.
During the last 5 trading sessions, ALVO rose by +10.17%, which changed the moving average for the period of 200-days by +66.07% in comparison to the 20-day moving average, which settled at $12.46. In addition, Alvotech saw 18.03% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ALVO
Current profitability levels for the company are sitting at:
- -3.88 for the present operating margin
- -0.76 for the gross margin
The net margin for Alvotech stands at -6.03. The total capital return value is set at -0.51.
Based on Alvotech (ALVO), the company’s capital structure generated 7.52 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at -1.15. The interest coverage ratio of the stock is -2.66.
Currently, EBITDA for the company is -334.64 million with net debt to EBITDA at -3.18. When we switch over and look at the enterprise to sales, we see a ratio of 50.93. The receivables turnover for the company is 1.05for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
In conclusion, Alvotech (ALVO) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
